Granocyte (Lenograstim)

Granocyte (lenograstim) is indicated for clinical situations where stimulation of white blood cell production is required.

• To reduce the duration of neutropenia in patients receiving myelosuppressive chemotherapy.
• To accelerate neutrophil recovery after autologous or allogeneic stem cell transplantation.
• To support hematopoietic recovery in patients with severe chronic neutropenia.
• To mobilize peripheral blood stem cells for collection prior to transplantation.

The safety profile of lenograstim includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common

• Bone pain, often in the lower back or limbs.
• Mild fever or flu‑like symptoms.
• Injection site reactions such as redness or swelling.

Serious

• Splenic enlargement or rupture.
• Severe allergic reactions, including anaphylaxis.
• Thromboembolic events such as deep vein thrombosis.

When prescribing or administering Granocyte, healthcare professionals should consider several precautionary measures to minimize risk.

• Assess baseline neutrophil count and overall bone marrow function before initiating therapy.
• Monitor for signs of splenomegaly during treatment, especially in patients with pre‑existing splenic conditions.
• Use the lowest effective dose and limit duration to reduce the likelihood of bone pain and other adverse effects.
• Avoid concurrent use with other myeloid growth factors unless specifically indicated.
• Evaluate for hypersensitivity history; discontinue if an allergic reaction occurs.
• Exercise caution in patients with a history of thromboembolic disease.

Lenograstim may interact with other medications or clinical conditions, requiring careful assessment to avoid adverse outcomes.

Avoid

• Concurrent administration with other granulocyte colony‑stimulating factors (e.g., filgrastim) unless directed.
• Use with investigational agents that suppress bone marrow function without medical supervision.

Use with caution

• Anticoagulants or antiplatelet agents, due to potential increased risk of thrombosis.
• Corticosteroids, which may mask signs of infection.
• Chemotherapy regimens, requiring timing adjustments to align with neutrophil recovery.